"Patience is a Super Power" - "The Money is in the waiting"

Saturday, September 19, 2026

From Qualcomm and IONQ to some high tech microcaps, a list of our recent articles/stocks buys

 Here is a re-cap of our most recent articles and stock buys:

June 2026

Kraken Robotics acquisition of Coveya and it's subsidiaries will make this a much larger, international player in the subsea robotics market! 

Monday, September 14, 2026

Could there be a re-awakening of Recursion Pharmaceuticals stock this year? It looks that way!

 


RXRX has several identifiable catalysts between now and year-end 2026 that could materially move the shares, and the setup looks more interesting than it did when we last reviewed the company in August. The important distinction is that the next move is likely to be driven by clinical validation, not simply enthusiasm for “AI drug discovery.”

RXRX — What could move the stock before year-end?

1. REC-4881: November looks like the biggest near-term catalyst

This is the event I would put at the top of the list.

Recursion has confirmed that additional Phase 2 data for REC-4881 in familial adenomatous polyposis (FAP) will be presented in a Presidential Plenary session at a leading hereditary gastrointestinal meeting in November 2026.

REC-4881 is important because the earlier data showed rapid and durable reductions in polyp burden, and there currently are no FDA-approved pharmacotherapies specifically for FAP. Recursion is also discussing the program with the FDA and sees a potential path toward a registrational study.

Potential stock impact: HIGH.

If November's larger dataset confirms meaningful efficacy, acceptable tolerability and durability—and particularly if Recursion provides a credible FDA/registrational path—I think this could become the event that changes the market's perception of RXRX from:

“Interesting AI drug-discovery company”

to

“AI drug-discovery company that may actually have produced a commercially viable medicine.”

That distinction is enormous.


2. REC-1245: another H2 2026 clinical readout

This one may actually have greater upside surprise potential.

Recursion expects additional Phase 1 monotherapy dose-escalation data for REC-1245 during H2 2026. REC-1245 is an RBM39 degrader targeting difficult, genomically unstable cancers and originated from Recursion's AI/Bio platform work around CDK12 biology.

Management estimates more than 100,000 potentially addressable patients, although that is obviously a very early-stage commercial estimate rather than anything approaching forecast revenue.

Potential stock impact: HIGH, but higher risk than REC-4881.

Good early efficacy signals could be particularly powerful because they would provide another independent piece of evidence that Recursion's discovery engine can generate useful drugs.


3. REC-7735 is moving into humans

There's another development I think deserves more attention.

The FDA has cleared the IND for REC-7735, Recursion's PI3Kα H1047R inhibitor, and the company expects the Phase 1/2 study to begin during H2 2026.

Recursion describes the compound as having >100× selectivity for mutant PI3Kα H1047R versus wild-type PI3Kα. The investment thesis is that this could potentially suppress the cancer-driving mutation more deeply while avoiding some toxicity associated with inhibiting normal PI3Kα.

2026 stock impact: MODERATE.

Trial initiation isn't nearly as important as actual clinical data, but it adds another credible clinical asset to the pipeline.


4. Roche/Genentech may be the sleeper catalyst

This development is particularly important to the AI thesis.

Genentech recently advanced the first neuroscience target discovered through the Recursion collaboration into a joint early-discovery program. Recursion calls this early evidence that its platform can generate novel, biologically validated drug targets.

And there could be additional Roche/Genentech target milestones.

This matters because outside validation from a sophisticated pharmaceutical company can arguably be more valuable to RXRX's platform valuation than another impressive AI model demonstration.

If Genentech selects additional Recursion-generated targets, investors may begin assigning greater value to the Recursion OS itself, rather than valuing RXRX primarily as a collection of experimental drugs.

Potential impact: MODERATE-HIGH.


5. Sanofi could provide another validation event

Recursion says its joint programs with Sanofi have made significant progress toward development-candidate designation.

Management specifically identifies potential development-candidate and late-stage discovery milestones over the coming 12 months, following an oral first-in-class oncology lead-series milestone during 2026.

This is important because successful Sanofi + Roche/Genentech programs would demonstrate that the Recursion platform is repeatable across different pharmaceutical partners.


6. The financial story has improved

This isn't as exciting as clinical data, but it reduces one of my biggest concerns with RXRX: cash burn and dilution.

At June 30 Recursion had approximately $556.8 million of cash, cash equivalents and restricted cash and expects its runway to extend into early 2028 without additional financing. Management also reduced expected 2026 cash operating expenses to below $375 million, versus previous guidance below $390 million.

That's roughly a 40% reduction in cash operating expense compared with pro-forma 2024.

That gives management considerably more breathing room to reach the upcoming clinical milestones before needing additional capital.


My RXRX catalyst ranking

CatalystTimingPotential stock impact
REC-4881 additional Phase 2 dataNovember 2026🔥🔥🔥🔥🔥
REC-4881 FDA/regulatory updateH2 2026🔥🔥🔥🔥🔥
REC-1245 additional Phase 1 dataH2 2026🔥🔥🔥🔥
Additional Roche/Genentech targets2026–27🔥🔥🔥🔥
Sanofi development milestones2026–27🔥🔥🔥
REC-7735 Phase 1/2 initiationH2 2026🔥🔥
Further expense/runway improvementQ3/Q4🔥🔥

What has changed in my investment view

I would now characterize RXRX as a speculative accumulation candidate ahead of the November REC-4881 data, rather than simply an AI-biotech stock to watch.

There is a potentially powerful three-layer catalyst structure developing:

Clinical validation → Big Pharma validation → AI-platform validation.

REC-4881 and REC-1245 address the first. Roche/Genentech and Sanofi address the second. If both occur simultaneously, they begin validating the third—and that is where the really large valuation change could eventually occur.

The downside is equally important: poor REC-4881 or REC-1245 data could hit RXRX hard. This remains clinical-stage biotech, and the stock should be sized accordingly.

My current view

Speculative rating: 8.5/10

Most important date/window: November 2026

Most important asset: REC-4881

Potential surprise asset: REC-1245

Most important external validation: Roche/Genentech

Biggest risk: clinical results fail to validate the promise of the AI discovery platform.

Ed Note:

 I am more inclined to hold/add selectively into weakness ahead of the November catalyst than sell the position now. But I will not make the position oversized before seeing the REC-4881 data.

I will monitor RXRX through the November REC-4881 presentation and alert you if a new clinical, FDA, Sanofi or Roche/Genentech catalyst appears.

Recursion Pharmaceuticals investor relations

Previous articles:

Aug 19th 2026

Adding to RXRX, Recursion Pharmaceuticals Stocks today!

Sunday, September 13, 2026

Canada Nickel is speculative, but the upside could be enormous. We took a small position!

 


Canada Nickel Company (TSXV: CNC) — Investment Note

September 2026 | Speculative Buy / Accumulate

Canada Nickel Company is becoming increasingly interesting around the C$1.40 area. The investment thesis is gradually shifting from “Will the massive Crawford Nickel Project ever be built?” toward the more important question of “How will Crawford be financed, and how much dilution will existing shareholders face?”

The case has improved materially. Crawford has received its positive federal Decision Statement, removing a major regulatory hurdle, while Canada Nickel is targeting a 2027 construction decision. The company is developing a financing structure incorporating debt, government investment tax credits, strategic investment and equity. Importantly, EDC has provided a US$500-million financing letter of interest, while refundable federal investment tax credits could potentially contribute hundreds of millions toward development costs.

Canada Nickel also has unusually strong strategic backing for a junior developer. Agnico Eagle, Samsung SDI and Anglo American are significant shareholders. Their involvement doesn't guarantee Crawford's success, but it provides valuable third-party validation of both the deposit and its potential strategic importance to North America's critical-minerals supply chain.

The principal risk remains financing. Crawford is a multi-billion-dollar project, CNC remains a pre-production company, and nickel prices continue to face pressure from abundant Indonesian supply. Significant equity issuance could dilute existing shareholders. For that reason, CNC should be considered a high-risk, high-upside development-stage investment rather than a conventional mining stock.

Investment Approach

At approximately C$1.40–C$1.45, I would consider establishing or adding to a starter position rather than buying the entire intended position immediately. Further weakness toward C$1.25–C$1.35 would provide a more attractive accumulation opportunity, assuming the Crawford thesis remains intact.

Investment Rating: 8.5/10 — Speculative Buy/Accumulate

The single most important catalyst to watch is now Crawford financing. If Canada Nickel can demonstrate that this enormous project can be financed through government incentives, EDC and other debt, strategic partners and limited equity issuance—without severely diluting existing shareholders—the market could begin valuing CNC very differently. That is where I believe the largest potential re-rating opportunity lies.


Thursday, September 10, 2026

Volatus Aerospace just got a real "shot in the arm" from CAF

 


Volatus Aerospace (TSX: FLT): Today's CAF Breakthrough Changes the Investment Case

September 10, 2026

Volatus Aerospace has just crossed an important threshold in its evolution from an emerging Canadian drone company into a potentially significant Canadian aerospace and defence contractor. The Government of Canada has awarded Volatus a five-year contract to supply Low-Cost Tactical ISR drone systems to the Canadian Armed Forces, beginning with 100 systems and providing Canada with options for as many as 4,900 additional systems — 5,000 in total and a potential procurement envelope of C$25 million. Initial deliveries are expected in Q4 2026.

The immediate revenue is not what makes this announcement particularly important. The additional 4,900 systems are options, not guaranteed orders or backlog. Rather, this is the first conversion of Volatus' qualification under Canada's new Defence Drone Initiative (DDI) Marketplace into an actual CAF procurement contract. Just two days earlier, Volatus announced that it had qualified across all five DDI streams, covering autonomous systems, communications, engineering/integration, testing/training and innovation.

Why This Matters

The contract validates several pieces of the investment thesis simultaneously. Volatus now has the Canadian Armed Forces as a direct customer, its Mirabel manufacturing and systems-integration strategy gains credibility, and the company is supplying considerably more than aircraft. The contract includes payloads, ground-control stations, data links, training, sustainment, spare parts, documentation and software/firmware support. That integrated model potentially creates recurring service and support revenue and moves Volatus toward becoming a Canadian UAS systems integrator rather than simply a drone distributor.

The timing is also important. Volatus entered this growth phase with approximately C$59.2 million in cash and C$63.8 million in working capital at June 30. Its Q2 revenue increased 49.5% sequentially to C$8.42 million, while its Mirabel manufacturing and integration facility became operational. Volatus therefore has substantially more financial and physical capacity to pursue larger defence programs than it had previously.

The Bigger Opportunity

The C$25-million potential value of this particular program should not be confused with the size of the longer-term opportunity. Volatus is qualified to compete across all five streams of Canada's DDI Marketplace through a procurement framework extending into 2031. Today's win demonstrates that the mechanism can actually convert Volatus' qualification into CAF business.

That creates the possibility of a much more important sequence:

CAF validation → larger follow-on orders → additional DDI contracts → recurring training/software/sustainment revenue → NATO/allied opportunities → manufacturing scale → profitability.

Investment View

We believe today's announcement materially strengthens and partially de-risks the FLT investment thesis. One of our principal anticipated catalysts — a meaningful Canadian Armed Forces procurement — has now occurred.

There remains substantial risk. Volatus is not yet profitable; Q2 adjusted EBITDA was a C$4.35-million loss, and investors should not treat the optional 4,900 systems as guaranteed revenue. The next critical evidence will be Canada exercising those options, additional DDI/CAF awards, growing defence backlog and progress toward positive EBITDA.

Our conclusion: Volatus remains a speculative small-cap investment, but the story has changed. FLT is no longer simply positioned to benefit from Canada's rapidly expanding drone and defence strategy — it has begun converting that position into actual Canadian Armed Forces business.

For a growth investor willing to accept small-cap volatility and execution risk, we believe FLT remains one of the more interesting publicly traded Canadian pure-play opportunities in drones, autonomous systems and the rebuilding of Canada's sovereign defence capability.

I would now make “CAF follow-on orders and the first exercise of the 4,900-system option” the most important near-term metric in our continuing FLT investment thesis.

Related Articles

Volatus Aerospace (FLT.t) is one of those hidden gems in the smallcap/microcap space. Here's why!

Tuesday, September 8, 2026

IONQ has effectively assembled a quantum conglomerate!

 


IonQ — Updated Business & Investment Report

September 8, 2026 | NYSE: IONQ

Today's announcement materially strengthens the IonQ investment thesis. The important development is not simply that IonQ has announced a 256-physical-qubit machine. It is that Superion 256 is the first product built around an architecture IonQ intends to manufacture repeatedly and scale toward fault tolerance, while the recently acquired SkyWater gives IonQ direct control over much of the semiconductor fabrication needed to execute that roadmap.

My updated view is that IonQ has evolved from one of several promising quantum-computing companies into something substantially broader: a vertically integrated quantum technology platform spanning compute, fabrication, networking, photonics, sensing, security and software.

That does not mean IonQ has won quantum computing. IBM, Google, Quantinuum and others remain formidable competitors. But among publicly traded pure-play quantum companies, I believe IonQ now has the most complete strategic architecture for turning quantum technology into a large commercial business.


1. The September 8 announcement changes the story

6

IonQ today unveiled Superion 256, its sixth-generation quantum-computing platform. The important specifications are:

  • 256 physical trapped-ion qubits
  • first fully integrated 256-qubit QPUs already fabricated at SkyWater
  • ions have already been trapped in a prototype system
  • orders are being accepted
  • customer deliveries are planned for 2027
  • Superion becomes the underlying platform on which IonQ expects subsequent compute products to be built.

That last point matters most.

This isn't supposed to be a one-off 256-qubit laboratory machine.

Superion is intended to become a scalable product architecture.


2. The significance of SkyWater is becoming much clearer

IonQ completed its roughly $1.8-billion acquisition of SkyWater on July 31. SkyWater brings U.S.-based semiconductor fabrication, advanced packaging and manufacturing capabilities directly inside IonQ.

Today's announcement provides the first particularly tangible evidence for the strategic logic of that acquisition:

IonQ isn't merely talking about manufacturing integration—the first Superion chips have already been fabricated at SkyWater.

That potentially removes one of the biggest problems facing quantum startups:

How do you get from an excellent laboratory experiment to manufacturing thousands—and eventually millions—of repeatable quantum components?

IonQ is attempting to solve that problem internally.

Previously the chain looked approximately like:

IonQ design → outside fabrication → packaging → integration → IonQ quantum computer

It increasingly becomes:

IonQ architecture → IonQ/SkyWater fabrication → packaging → trapped-ion QPU → IonQ system → IonQ network → IonQ software

That vertical integration is unusual in quantum computing.

SkyWater also continues operating as a merchant semiconductor foundry, meaning IonQ potentially obtains a second business model: supplying technologies and fabrication services to the broader quantum ecosystem.


3. IonQ has effectively assembled a quantum conglomerate

This is where I think investors can underestimate what IonQ management has been doing.

The acquisitions increasingly resemble pieces of one architecture.

CapabilityIonQ / acquired technologyStrategic purpose
Quantum processorsIonQTrapped-ion quantum computing
Electronic qubit controlOxford IonicsScalable ion control
Semiconductor fabricationSkyWaterQPU manufacturing
Photonic interconnectLightsynqConnect quantum processors
Quantum memoryLightsynqDistributed quantum computing
Integrated photonicsNexus PhotonicsOptical integration
Quantum networkingQubitekk / ID QuantiqueQuantum internet
Quantum securityIDQQuantum-safe communications
Quantum sensingVector AtomicTiming/navigation/sensing
Space networkingCapella/Skyloom capabilitiesSpace-based infrastructure
Software/automationSeed InnovationsEnterprise/cloud integration

IonQ completed the Oxford Ionics acquisition in September 2025, adding patented trapped-ion control technology, while Lightsynq brought photonic interconnect and quantum-memory capabilities designed specifically to help connect quantum processors into larger systems.

This is increasingly analogous to building the pieces required for a quantum data centre, rather than simply building a quantum computer.


4. Walking Cat may ultimately be more important than Superion

The Walking Cat architecture announced in April is the intellectual foundation underlying the roadmap.

IonQ describes it as an end-to-end architecture covering error correction, logical architecture, compiler and physical machine design.

Its significance is straightforward.

Today's quantum computers have physical qubits.

Useful fault-tolerant quantum computing requires logical qubits protected by error correction.

Walking Cat is IonQ's proposed bridge between the two.

IonQ's updated roadmap is extraordinarily ambitious:

YearPhysical qubitsLogical qubits
2026100–256+12
202710,000800
202820,0001,600
2029200,0008,000
20302,000,00080,000

IonQ is targeting approximately 99.99% physical-qubit fidelity through this scaling trajectory.

This is where SkyWater, Oxford Ionics and Lightsynq begin fitting together.

**IonQ trapped ions

  • Oxford electronic control
  • SkyWater manufacturing
  • Lightsynq/Nexus photonic interconnects
  • Walking Cat error correction
    = distributed fault-tolerant quantum computing.**

That is a much more compelling architecture than simply attempting to construct one gigantic quantum processor.


5. It reinforces the networked-computer thesis

One aspect of IonQ's strategy that I consider particularly attractive is modular scaling.

Eventually there are practical limits to how many qubits can conveniently be controlled inside a single quantum processing unit.

The alternative is analogous to classical supercomputing:

build many powerful processors and connect them.

Lightsynq's photonic interconnect technology is intended to allow separate trapped-ion processors to communicate quantum mechanically. IonQ has already demonstrated two connected commercial quantum computers, an important early step toward distributed quantum computing.

This potentially produces:

QPU → quantum node → interconnected nodes → quantum data centre → quantum network

And eventually:

quantum internet.

That is why I continue to regard IonQ's networking acquisitions as strategically important rather than peripheral.


6. IonQ also delivered an important cryptography result today

Today's Superion announcement somewhat overshadowed another potentially important development.

IonQ published what it describes as the first fully compiled end-to-end resource estimate for using Shor's algorithm against 256-bit elliptic-curve cryptography.

Using Walking Cat, IonQ estimates that approximately:

20,000 physical qubits

could attack secp256k1 in approximately:

26 days.

Importantly, such a machine does not exist today. IonQ itself explicitly notes that no current computer can execute this attack.

But compare the requirement with the roadmap:

2028 target: ~20,000 physical qubits / 1,600 logical qubits.

That illustrates why IonQ simultaneously wants to own quantum computing and quantum security.

The same technology potentially creates the cryptographic threat—and the commercial demand for quantum-safe networks.


7. Financial performance is finally becoming meaningful

This part of the IonQ story has changed dramatically.

Q2 2026

IonQ reported:

MetricQ2 2026
Revenue$80.1M
YoY revenue growth287%
Cash + investments$3.0B
Pro-forma cash after SkyWater~$2.0B
Adjusted EBITDA loss($120.3M)
Adjusted EPS($0.33)

Revenue exceeded the midpoint of guidance by approximately 20%.

More importantly, the composition is improving:

  • roughly 50% international
  • roughly 60% commercial
  • approximately 25% multi-product.

That suggests IonQ is becoming less dependent upon isolated U.S. government research contracts.


8. Don't be frightened by the $1.87-billion GAAP Q2 loss without understanding it

The headline GAAP loss was enormous:

$1.868 billion / $5.08 per share.

But it badly exaggerates the underlying operating loss.

Approximately $1.576 billion resulted from changes in fair-value measurements. IonQ's adjusted EPS loss was $0.33, and adjusted EBITDA loss was $120.3 million.

The company is unquestionably burning substantial cash as it invests aggressively.

But IonQ is not economically losing nearly $1.9 billion every quarter in normal operations.

That's an important distinction.


9. Today's revenue-guidance increase is significant

Immediately following Q2, IonQ guided to:

$280–290 million 2026 revenue

excluding SkyWater.

Today management updated consolidated guidance to:

$450–460 million

including SkyWater only from its July 31 acquisition date onward and eliminating intercompany revenue between SkyWater and IonQ.

Compare the progression:

2025 actual revenue: $130M
2026 original guidance: $225–245M
after Q1: $260–270M
after Q2: $280–290M
September 8 combined guidance: $450–460M

That is an extraordinary change in scale.

Some of it is acquisition-driven, so investors should not interpret $455 million as purely organic quantum-computing growth. But IonQ still expects roughly 100% organic growth in its legacy business.


10. What should we expect from Q3?

IonQ has not yet officially announced the Q3 reporting date in the materials I found. Third-party earnings calendars currently place it in early-to-mid November, so I would treat any precise date or consensus EPS number as provisional rather than company guidance.

More important than EPS will be five things:

  1. Organic IonQ revenue growth
  2. SkyWater revenue and margin contribution
  3. Superion customer orders
  4. cash burn following the acquisition spree
  5. evidence that the 2027/2028 technical milestones remain on schedule

The first combined IonQ/SkyWater quarter is going to make historical comparisons considerably messier.

I would therefore focus less on headline GAAP EPS and much more on organic revenue, RPO/bookings, adjusted EBITDA, cash consumption and technical milestones.


11. Does IonQ now lead quantum computing?

This requires an important qualification.

I would not say IonQ is definitively ahead of every quantum company.

IBM has tremendous quantum expertise and enterprise relationships. Google has demonstrated exceptionally important quantum-error-correction research. Quantinuum remains arguably IonQ's closest trapped-ion technological competitor.

My current technology ranking (of the "pure plays")

RankCompanyArchitectureWhy it mattersMy rating
1IonQTrapped ionFull-stack strategy, SkyWater manufacturing, networking, photonics, Superion/Walking Cat9.5/10
2QuantinuumTrapped ionExceptional fidelity, 50 logical qubits, advanced QEC, Helios commercially available9.4/10
3InfleqtionNeutral atomPotentially excellent scalability + sensing/timing businesses8.7/10
4D-WaveAnnealing + gate modelMost commercially mature specialized quantum approach8.3/10
5RigettiSuperconductingFast gates, in-house fabrication, but fidelity remains an issue7.8/10

The gap between #1 and the other publicly traded pure plays has, in my assessment, widened during 2026.


12. The most important competitive advantage may be something investors aren't valuing yet

Consider what IonQ now owns.

A competitor wanting to build a large quantum computer may need:

  • semiconductor fabrication
  • advanced packaging
  • ion-trap hardware
  • control electronics
  • lasers
  • photonics
  • quantum memory
  • networking
  • error correction
  • software
  • cybersecurity
  • manufacturing expertise.

IonQ now has all those capabilities internally.

That opens the possibility of IonQ eventually selling more than IonQ computers.

It could become a merchant supplier to the quantum industry.

That is precisely why management keeps using the analogy:

"NVIDIA of quantum."

I would not take that comparison literally—IonQ is nowhere remotely close to NVIDIA's economics, market position or profitability.

But strategically, the aspiration makes sense.

Instead of betting solely on selling complete quantum computers, IonQ wants to provide the infrastructure upon which other quantum systems and applications can be built.


13. Major investment risks

This remains an extremely speculative stock.

The largest risk is execution against the roadmap.

Moving from 256 physical qubits to:

10,000 → 20,000 → 200,000 → 2,000,000

in only four years is an extraordinary engineering challenge.

The second is acquisition integration. IonQ has assembled an enormous number of technologies and organizations very quickly.

Third is dilution and capital allocation. Acquisitions such as the roughly $1.8-billion SkyWater transaction and approximately $1-billion Oxford Ionics acquisition are substantial relative to IonQ's size.

Fourth is valuation. Investors are already paying heavily for technological success that won't be demonstrated for several years.

And finally, competitors will not stand still.


14. What would make the thesis fail?

I would become materially more cautious if IonQ:

misses the 10,000-qubit 2027 target, cannot demonstrate scalable error correction, experiences meaningful deterioration in fidelity as qubit counts increase, fails to demonstrate photonic interconnection between larger processors, burns through cash substantially faster than expected, or repeatedly pushes its fault-tolerant roadmap backward.

Conversely, successful execution of the 2027 10,000-physical-qubit / 800-logical-qubit milestone would be one of the most important technical validations in the company's history.


15. Updated Investment Scorecard

CategoryMy assessment
Core quantum technology10/10
Fault-tolerance strategy10/10
Manufacturing strategy10/10
Quantum networking10/10
Vertical integration10/10
Commercial traction9/10
Revenue growth10/10
Balance sheet9/10
Profitability3/10
Valuation4/10
Execution riskHigh
Long-term upsideExceptional

Overall speculative-growth rating: 9.3/10


Investment conclusion

My IonQ thesis has actually strengthened following today's announcement.

Previously, the investment case largely rested on the belief that IonQ's trapped-ion architecture, high fidelity and networking strategy could eventually produce scalable fault-tolerant quantum computing.

Today we have another piece of evidence.

SkyWater has fabricated the Superion processors.
The prototype is trapping ions.
Superion is being offered commercially.
Walking Cat defines the fault-tolerant architecture.
Lightsynq/Nexus provide the photonic scaling path.
Oxford Ionics provides additional control technology.
SkyWater provides manufacturing.

And IonQ now guides to approximately $450–460 million of 2026 consolidated revenue while retaining roughly $2 billion of pro-forma cash/investments following the SkyWater transaction.

The distinction is increasingly important:

IonQ is no longer merely trying to build a better quantum computer.

It is trying to build the industrial infrastructure for quantum computing.

That is why I believe today's Superion announcement is more important than the jump from 100 to 256 physical qubits might initially suggest. Superion + Walking Cat + SkyWater + Oxford Ionics + Lightsynq/Nexus gives IonQ a credible architecture for moving from hundreds of physical qubits to thousands, then potentially tens or hundreds of thousands of interconnected qubits.

For a long-term speculative investor, I would therefore continue to regard IONQ as the premier publicly traded pure-play quantum holding, while recognizing that the valuation demands substantial technical execution.

The next major inflection point isn't simply Q3 earnings.

It is evidence that Superion can become a manufacturing platform rather than merely another quantum machine.

If IonQ demonstrates that—and then credibly moves toward 10,000 physical / 800 logical qubits in 2027—the argument that IonQ is developing into the platform company of the quantum industry becomes considerably harder to dismiss.

IonQ's Superion 256 announcement
IonQ's updated 2026 financial outlook
IonQ's technology roadmap
IonQ Investor Relations